Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 14/20 | 0.51 |
| ▸ | LYN | P07948 | 11/20 | 0.51 |
| ▸ | SRC | P12931 | 10/20 | 0.51 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.51 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.51 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29498177 | 0.88 | RIPK2 (0.52) | BTKLYNSRCRIPK2ACVR1 | |
| SCHEMBL5061333 | 0.88 | ABL1 (0.44) | BTKLYNSRCRIPK2ACVR1 | |
| SCHEMBL16193772 | 0.85 | RIPK2 (0.44) | BTKLYNSRCRIPK2ACVR1 | |
| SCHEMBL16194057 | 0.85 | RIPK2 (0.46) | BTKLYNSRCRIPK2ACVR1 | |
| SCHEMBL21990257 | 0.84 | ABL1 (0.53) | SRCRIPK2ACVR1NOD2EGFR | |
| SCHEMBL5764679 | 0.82 | FGFR1 (0.64) | BTKSRCEGFRFGFR1 | |
| SCHEMBL4713056 | 0.82 | FGFR4 (0.51) | BTKLYNSRCRIPK2ACVR1 | |
| SCHEMBL16194033 | 0.82 | EGFR (0.42) | BTKLYNSRCRIPK2ACVR1 | |
| SCHEMBL4566794 | 0.81 | BRD4 (0.38) | BTKLYNSRCRIPK2ACVR1 | |
| SCHEMBL5264435 | 0.80 | FGFR1 (0.37) | BTKSRCEGFRFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624032-B2 | Pyrido[2,3-d]pyrimidin-7-ones and related compounds as inhibitors of protein kinases | UNIVERSITY OF HOUSTON SYSTEM (US) | 2026-05-12 | — | — | US | disclosed |
| US-12516055-B2 | Protein kinase inhibitors and uses thereof for the treatment of diseases and conditions | TRUSTEES OF TUFTS COLLEGE (US) | 2026-01-06 | — | — | US | disclosed |
| EP-4480485-A2 | PROTEIN KINASE INHIBITORS AND USES THEREOF FOR THE TREATMENT OF DISEASES AND CONDITIONS | University of Houston System (US) | 2024-12-25 | — | — | EP | disclosed |
| US-20240327403-A1 | PYRIDO[2,3-d]PYRIMIDIN-7-ONES AND RELATED COMPOUNDS AS INHIBITORS OF PROTEIN KINASES | UNIVERSITY OF HOUSTON SYSTEM (US) | 2024-10-03 | — | — | US | disclosed |
| EP-3968991-B1 | PROTEIN KINASE INHIBITORS AND USES THEREOF FOR THE TREATMENT OF DISEASES AND CONDITIONS | UNIV HOUSTON SYSTEM (US) | 2024-07-31 | — | — | EP | disclosed |
| US-12012402-B2 | Pyrido[2,3-d]pyrimidin-7-ones and related compounds as inhibitors of protein kinases | UNIVERSITY OF HOUSTON SYSTEM (US) | 2024-06-18 | — | — | US | disclosed |
| US-20220194937-A1 | PROTEIN KINASE INHIBITORS AND USES THEREOF FOR THE TREATMENT OF DISEASES AND CONDITIONS | UNIVERSITY OF HOUSTON SYSTEM | 2022-06-23 | — | — | US | disclosed |
| EP-3968991-A1 | PROTEIN KINASE INHIBITORS AND USES THEREOF FOR THE TREATMENT OF DISEASES AND CONDITIONS | University of Houston System (US) | 2022-03-23 | — | — | EP | disclosed |
| US-20220064163-A1 | PYRIDO[2,3-d]PYRIMIDIN-7-ONES AND RELATED COMPOUNDS AS INHIBITORS OF PROTEIN KINASES | UNIVERSITY OF HOUSTON SYSTEM (US) | 2022-03-03 | — | — | US | disclosed |
| US-11174255-B2 | Pyrido[2,3-d]pyrimidin-7-ones and related compounds as inhibitors of protein kinases | UNIVERSITY OF HOUSTON SYSTEM (US) | 2021-11-16 | — | — | US | disclosed |
| WO-2011090666-A2 | METHODS FOR TREATING AUTISM | AFRAXIS, INC. (US) | 2011-07-28 | — | — | WO | disclosed |
| WO-2011090666-A2 | METHODS FOR TREATING AUTISM | AFRAXIS, INC. (US) | 2011-07-28 | — | — | WO | disclosed |
| WO-2011063415-A2 | METHODS FOR TREATING MILD COGNITIVE IMPAIRMENT | AFRAXIS, INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| WO-2011063415-A2 | METHODS FOR TREATING MILD COGNITIVE IMPAIRMENT | AFRAXIS, INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| WO-2011044537-A2 | METHODS FOR TREATING ALZHEIMER'S DISEASE | AFRAXIS, INC. (US) | 2011-04-14 | — | — | WO | disclosed |
| WO-2011044537-A2 | METHODS FOR TREATING ALZHEIMER'S DISEASE | AFRAXIS, INC. (US) | 2011-04-14 | — | — | WO | disclosed |
| WO-2011009097-A2 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS, INC. (US) | 2011-01-20 | — | — | WO | disclosed |
| WO-2011009097-A2 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS, INC. (US) | 2011-01-20 | — | — | WO | disclosed |
| WO-2010071846-A2 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | AFRAXIS, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
| WO-2010071846-A2 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | AFRAXIS, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11174255-B2 | Pyrido[2,3-d]pyrimidin-7-ones and related compounds as inhibitors of protein kinases | RIPK2, RIPK1, RIPK4 | BTK 2170/4885LYN 558/4885SRC 2434/4885 |
| US-20240327403-A1 | PYRIDO[2,3-d]PYRIMIDIN-7-ONES AND RELATED COMPOUNDS AS INHIBITORS OF PROTEIN KINASES | RIPK2, RIPK1, RIPK4 | BTK 1937/4885LYN 574/4885SRC 2385/4885 |
| US-20220064163-A1 | PYRIDO[2,3-d]PYRIMIDIN-7-ONES AND RELATED COMPOUNDS AS INHIBITORS OF PROTEIN KINASES | RIPK2, RIPK1, RIPK4 | BTK 1937/4885LYN 574/4885SRC 2385/4885 |
| US-12012402-B2 | Pyrido[2,3-d]pyrimidin-7-ones and related compounds as inhibitors of protein kinases | RIPK2, RIPK1, RIPK4 | BTK 1937/4885LYN 574/4885SRC 2385/4885 |
| US-20220194937-A1 | PROTEIN KINASE INHIBITORS AND USES THEREOF FOR THE TREATMENT OF DISEASES AND CONDITIONS | RIPK2, RIPK1, RIPK4 | BTK 2439/4885LYN 645/4885SRC 1967/4885 |
| US-12624032-B2 | Pyrido[2,3-d]pyrimidin-7-ones and related compounds as inhibitors of protein kinases | RIPK2, RIPK1, RIPK4 | BTK 291/4885LYN 230/4885SRC 994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.